Reply to V. Amoroso et al.

Yao, James C; Voi, Maurizio; Lincy, Jeremie; Pavel, Marianne

Yao, James C; Voi, Maurizio; Lincy, Jeremie; Pavel, Marianne.

Afiliación

Yao JC; James C. Yao, University of Texas/MD Anderson Cancer Center, Houston, TX; Maurizio Voi, Novartis Pharmaceuticals Corporation, East Hanover, NJ; Jeremie Lincy, Novartis Pharmaceuticals AG, Basel, Switzerland; and Marianne Pavel, Charité Universitätsmedizin Berlin, Berlin, Germany.
Voi M; James C. Yao, University of Texas/MD Anderson Cancer Center, Houston, TX; Maurizio Voi, Novartis Pharmaceuticals Corporation, East Hanover, NJ; Jeremie Lincy, Novartis Pharmaceuticals AG, Basel, Switzerland; and Marianne Pavel, Charité Universitätsmedizin Berlin, Berlin, Germany.
Lincy J; James C. Yao, University of Texas/MD Anderson Cancer Center, Houston, TX; Maurizio Voi, Novartis Pharmaceuticals Corporation, East Hanover, NJ; Jeremie Lincy, Novartis Pharmaceuticals AG, Basel, Switzerland; and Marianne Pavel, Charité Universitätsmedizin Berlin, Berlin, Germany.
Pavel M; James C. Yao, University of Texas/MD Anderson Cancer Center, Houston, TX; Maurizio Voi, Novartis Pharmaceuticals Corporation, East Hanover, NJ; Jeremie Lincy, Novartis Pharmaceuticals AG, Basel, Switzerland; and Marianne Pavel, Charité Universitätsmedizin Berlin, Berlin, Germany.

J Clin Oncol ; 35(13): 1488-1489, 2017 05 01.

Article en En | MEDLINE | ID: mdl-28113028

Asunto(s)

Neoplasias Pancreáticas; Everolimus; Humanos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas Límite: Humans Idioma: En Revista: J Clin Oncol Año: 2017 Tipo del documento: Article País de afiliación: Alemania

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google